ACE2 inhibitors for treatment of COVID-19

Antivirals are urgently needed to treat patients with Acute Respiratory Distress Syndrome (ADRS).

SARS-CoV-2 attaches to cells via the cell surface form of ACE2 expressed at relatively low levels in the lung.

Inhibitors that prevent the interaction with ACE2 or prevent its internalisation are hypothesised to be candidate antiviral agents for COVID-19.

In collaboration with Monash University, Department of Pharmacology and Department of Biochemistry, we will screen ACE2 inhibitors for their ability to prevent viral entry and replication, examine their mechanism of action and optimise the best performing candidates for formulation as an inhalant.


2020 -


  • Prof Robert Widdop, Monash University
  • Prof Mibel Aguilar, Monash University

Contact Details

For any general enquiries relating to this project, please contact:

Professor Heidi Drummer

Co-Program Director, Disease Elimination; Scientific Director, Burnet Diagnostics Initiative; Principal Investigator, Burnet Vaccine Initiative; Co-Head, Viral Entry and Vaccines Group